Powered by Clearbit
Bicycle Therapeutics plc (NMS: BCYC)+ to Company Analysis List
Address: Blocks A & B, Portway Building,Granta Park,Great Abington,Cambridge, CB21 6GS United Kingdom  |  Phone: (44) 122 326 1503  |  Company Website: www.bicycletherapeutics.com

Incorporated: October 2017 , United Kingdom

Auditor: PricewaterhouseCoopers LLP

Legal Counsel: Goodwin Procter LLP

Transfer Agent: Computershare Investor Services plc

Country:  United Kingdom

Industry: Biotechnology (ICB 20103010)

Industry: Pharmaceutical preparations (SIC 2834)

Industry: Pharmaceutical Preparation Manufacturing (NAICS 325412)

Number of Employees: 236 (Year End Average Staff as of 12/31/2022)

Number of Shareholders: 59 (approx. record) (as of 02/23/2023)

Market Cap: 102,258,800

Revenue: 39,574,000

Net Income: -165,372,000

EPS Basic: -3.78    EPS Diluted: -3.78

Industries & sectors Products & services Competitors Customers Suppliers Partners M&A scenario report
Download  Printer Friendly My Mergent Tools
Company Analysis List (0/500)
No company added to the Company Analysis List
Executive List (0/500)
No executive added to the Executive List
Mergent Private Company List (0/500)
No company added to the Mergent Private Company List
Company Alerts (0)
No alerts added to Alerts
Executive Alerts (0)
No alerts added to Executive Alerts

Focused ()  Healthcare  >  Outsourced Biomedical Services  >  Drug Discovery Services  >  Lead Discovery/Validation/Optimization  (^263315)


12 Tradenames Found
Displaying 1-12 first prev Page of 1 next last
Tradename Type
Bicycle Therapeutics - BT1718 (MT1-MMP targeting Bicycle Toxin Conjugate (BTC)) [Phase 1/Phase 2]-
Bicycle Therapeutics - BT1718 (MT1-MMP targeting Bicycle Toxin Conjugate (BTC)) [Phase 1/Phase 2]Non-Medical
Bicycle Therapeutics - BT5528 (EphA2 targeting Bicycle Toxin Conjugate (BTC)) [Phase 1/Phase 2]-
Bicycle Therapeutics - BT5528 (EphA2 targeting Bicycle Toxin Conjugate (BTC)) [Phase 1/Phase 2]Non-Medical
Bicycle Therapeutics - BT7401 (multivalent CD137 agonist) [Preclinical]Unassigned
Bicycle Therapeutics - BT7455 (EphA2/CD137 Bicycle TICA) [Preclinical]Unassigned
Bicycle Therapeutics - BT7480 (Nectin-4/CD137 Bicycle TICA) [Phase 1/Phase 2]Unassigned
Bicycle Therapeutics - BT8009 (Nectin-4 targeting Bicycle Toxin Conjugate (BTC)) [Phase 2/ Phase 3]-
Bicycle Therapeutics - BT8009 (Nectin-4 targeting Bicycle Toxin Conjugate (BTC)) [Phase 2/ Phase 3]Non-Medical
Bicycle Therapeutics - THR-149 (Plasma Kallikrein (PKal) Inhibitor) [Phase 2] [Bicycle > Oxurion License Agreement]-
Bicycle Therapeutics - THR-149 (Plasma Kallikrein (PKal) Inhibitor) [Phase 2] [Bicycle > Oxurion License Agreement]Non-Medical
Bicycle Therapeutics Ltd.General Medical